Jefferies reiterates Hana Biosciences at buy

Hana Biosciences Inc. was reiterated at buy with a $13 price target by Jefferies & Co., Inc. analyst Adam Walsh following resolution of GlaxoSmithKline litigation risk. GSK's 45-day window expired to sue Hana Biosciences for patent infringement. The analyst expects near-term pipeline news flow and Zensana approval in the first-half 2007. Shares of the South San Francisco, Calif.-based development-stage biopharmaceutical company were down 25 cents, or 2.92%, at $8.30. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.